NEPHROPLUS

Nephrocare Health Services Limited

Dialysis chain under Nephrocare and NephroPlus brands

Healthcare›Healthcare›Healthcare Services›Healthcare Service Provider

nephroplus.com

Ask AI

Key metrics

Price as of 2026-10-16

Stock price

₹614.35

Market cap

6,158 Cr

Stock P/E

80.2 · FY26

P/B

5.52

ROE (FY26)

6.9%

ROCE (FY26)

13.2%

Operating margin (FY26)

13.6%

Debt / equity (FY26)

0.07

OCF / EBITDA (FY26)

102.5%

OCF / EBITDA (3Y)

89.0%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

NephroPlus (Nephrocare Health Services) runs dialysis clinics for kidney patients in India and abroad, including the Philippines and Uzbekistan, and sells related healthcare products.

Company snapshot

5thBy market cap

Ranked among 10 companies in Healthcare Service Provider.

What we see

Positives

✓89% of operating profit came in as cash over the last three years — profits are backed by real cash.

1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

Metric	Dec 2025	Mar 2026	Jun 2026
Sales	260 Cr	266 Cr	282 Cr
Operating expenses (approx.)	199 Cr	212 Cr	218 Cr
EBITDA	61 Cr	54 Cr	64 Cr
OPM %	23.4%	20.2%	22.7%
Other income	3 Cr	12 Cr	7 Cr
Interest	6 Cr	3 Cr	2 Cr
Depreciation	22 Cr	26 Cr	25 Cr
Profit before tax	36 Cr	33 Cr	41 Cr
Tax %	11.3%	8.6%	22.1%
Net profit	32 Cr	30 Cr	32 Cr
EPS (₹)	₹3.43	₹3.03	₹3.19

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	437 Cr	566 Cr	756 Cr	999 Cr	Sign in free for the trailing twelve months
Operating expenses (approx.)	389 Cr	465 Cr	589 Cr	772 Cr	Sign in free for the trailing twelve months
EBITDA	49 Cr	101 Cr	167 Cr	227 Cr	Sign in free for the trailing twelve months
OPM %	11.1%	17.8%	22.0%	22.7%	Sign in free for the trailing twelve months
Other income	6 Cr	9 Cr	14 Cr	25 Cr	Sign in free for the trailing twelve months
Interest	16 Cr	20 Cr	21 Cr	60 Cr	Sign in free for the trailing twelve months
Depreciation	47 Cr	56 Cr	72 Cr	91 Cr	Sign in free for the trailing twelve months
Profit before tax	-9 Cr	33 Cr	87 Cr	97 Cr	Sign in free for the trailing twelve months
Tax %	-37.2%	-5.9%	23.3%	21.2%	Sign in free for the trailing twelve months
Net profit	-12 Cr	35 Cr	67 Cr	77 Cr	Sign in free for the trailing twelve months
EPS (₹)	₹-1.53	₹4.55	₹8.28	₹8.48	Sign in free for the trailing twelve months
Dividend payout %	—	—	—	0.0%	Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	2 Cr	2 Cr	2 Cr	20 Cr
Reserves	387 Cr	412 Cr	582 Cr	1,096 Cr
Borrowings	196 Cr	243 Cr	226 Cr	80 Cr
Other liabilities	81 Cr	149 Cr	187 Cr	275 Cr
Total liabilities	666 Cr	806 Cr	996 Cr	1,471 Cr
Fixed assets (net)	185 Cr	263 Cr	278 Cr	396 Cr
CWIP	32 Cr	0.69 Cr	6 Cr	6 Cr
Investments	—	—	51 Cr	178 Cr
Inventories	26 Cr	26 Cr	27 Cr	33 Cr
Trade receivables	159 Cr	203 Cr	266 Cr	317 Cr
Cash & bank	14 Cr	61 Cr	126 Cr	124 Cr
Other assets	250 Cr	253 Cr	243 Cr	418 Cr
Total assets	666 Cr	806 Cr	996 Cr	1,471 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	11 Cr	72 Cr	135 Cr	233 Cr
Cash from investing	-78 Cr	-51 Cr	-125 Cr	-410 Cr
Cash from financing	60 Cr	27 Cr	54 Cr	157 Cr
Net cash flow	-7 Cr	48 Cr	65 Cr	-2 Cr
Free cash flow (OCF − Capex)	-62 Cr	-8 Cr	35 Cr	113 Cr

Ratios

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026
ROCE %	1.3%	8.1%	13.4%	13.2%
ROE %	-3.0%	8.5%	11.5%	6.9%
Debtor days	132	131	128	115
Inventory days	67	56	50	53
Days payable	111	153	212	230
Cash conversion cycle	88	34	-33	-61
OCF / EBITDA %	23.2%	71.6%	81.2%	102.5%
OCF / EBITDA % (3 years)	—	—	69.2%	89.0%
Debt / equity	0.50	0.59	0.39	0.07
Current ratio	1.86	1.61	1.92	2.80
Net debt / EBITDA	3.75	1.81	0.60	-0.19